Skip to main content

Sensei Biotherapeutics, Inc.

Calidad de datos: 83%
SNSE
NASDAQ Manufacturing Chemicals
$29.21
▲ $0.51 (1.78%)
6 months return
Momentum
Neutral
ROE
-83.80%

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-83.80%
Below sector avg (-54.68%)
ROIC-68.96%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio5.81
Interest Coverage-696.50

Valoración

PE (TTM)
-1.95
Below sector avg (-1.49)
P/B Ratio1.79
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -20.47 M

Price History

Tendencias Financieras

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Sorpresas de Ganancias

EPS
Reported Estimate Forecast
Next: Q2 2026 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q2 '26
Reported -$5.40 -$3.91 -$3.62 -$3.74
Estimate -$5.20 -$5.00 -$4.11 -$4.81
Sorpresa -3.85% +21.80% +11.92% +22.25%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -83.80% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -21.09 M
ROE -83.80% ROA -71.03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -20.47 M
ROIC -68.96% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 5.81
Debt / Equity N/A Current Ratio 5.81
Interest Coverage -696.50 Asset Turnover N/A
Working Capital 21.35 M Tangible Book Value 23.01 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.95 · EV/EBITDA: N/A
P/E Ratio -1.95 Forward P/E N/A
P/B Ratio 1.79 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -49.75%
Market Cap 41.15 M Enterprise Value 30.58 M

Per Share

EPS: -16.72 · FCF/Share: -15.27
EPS (Diluted TTM) -16.72 Revenue / Share N/A
FCF / Share -15.27 OCF / Share -15.26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 97.08% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 97.08%
SBC-Adj. FCF -22.18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue
Net Income -21.09 M -30.16 M -34.10 M -48.59 M -36.79 M
EPS (Diluted) -16.72 -1.20 -1.22 -1.58
Gross Profit
Operating Income -22.29 M -32.61 M -37.06 M -50.19 M -37.48 M
EBITDA
R&D Expenses
SG&A Expenses
D&A 122,000.0 551,000.0 571,000.0 614,000.0 685,000.0
Interest Expense 32,000.0 90,000.0 144,000.0 219,000.0 670,000.0
Income Tax 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22.90 M 45.36 M 74.37 M 118.38 M 153.23 M
Total Liabilities 4.31 M 6.98 M 9.48 M 14.97 M 6.71 M
Shareholders' Equity 18.59 M 38.39 M 64.90 M 103.41 M 146.51 M
Total Debt 567,000.0
Cash & Equivalents 8.67 M 9.99 M 13.01 M 17.80 M 7.16 M
Current Assets 21.51 M 41.93 M 67.25 M 108.59 M 148.54 M
Current Liabilities 4.25 M 5.45 M 5.64 M 9.07 M 4.89 M

Comparación con Pares

vs mediana del sector Manufacturing (1605 pares)
Métrica Acción Mediana del Sector
P/E -2.0 -1.5
P/B 1.8 1.6
ROE % -83.8 -54.7
Net Margin % -41.5
Rev Growth 5Y % 1.8
D/E 0.3